ArticleEJIFCC2022
Variation of Total Anti-SARS-CoV-2 Antibodies After Primary BNT162b2 Vaccination and Homologous Booster.
Article in EJIFCC, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Evaluation of the Efficacy of BBIBP-CorV Inactivated Vaccine Combined with BNT62b2 mRNA Booster Vaccine.Diagnostics (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In this serosurveillance study, we investigated the variation of total anti-SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) antibodies in healthcare workers receiving primary BNT162b2 vaccination and homologous booster. Methods: A total number of 524 subjects (median age, 46 years; 65.3% females), were studied. All received primary BNT162b2 vaccination (two doses) and homologous booster (one dose) >8 months after completing the primary cycle. Blood samples were collected before the first and second vaccine doses, at 1, 3 and 6 months after the second dose, as well as before and 1 month after booster. Total anti-SARS-CoV-2 neutralizing antibodies were assayed with Roche Elecsys Anti-SARS-CoV-2 S chemiluminescent immunoassay. Results: Overall, 65.1% subjects were baseline (i.e., pre-vaccination) SARS-CoV-2 seronegative and always tested SARS-CoV-2 negative ("N/N"), 16.2% were baseline SARS-CoV-2 seronegative but tested SARS-CoV-2 positive after receiving the vaccine booster dose ("N/P"), whilst 18.7% were baseline SARS-CoV-2 seropositive and always tested SARS-CoV-2 negative afterwards ("P/N"). All groups displayed a similar trend of total anti-SARS-CoV-2 S antibodies throughout the study period, though the P/N cohort exhibited higher values compared to the other two groups until receiving the booster, after which the levels become similar in all cohorts. Significant differences in total anti-SARS-CoV-2 S antibodies values were not found between N/N and N/P groups, neither 1 month after booster. The rate of subjects with protective antibodies values become 100% in all groups after booster. Conclusions: Although baseline seropositivity is associated with more pronounced humoral immune response following primary vaccination compared to never infected subjects, SARS-CoV-2 infection after booster does not significantly foster antibody titers.
Indexed as
Identifiers
36313914PMC9562482What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.